Fujifilm pictures new pharma-heavy identity with Avigan

Looming end to Xerox tie-up strains push into health care

20200521N komori

Fujifilm Chairman and CEO Shigetaka Komori has been a driving force behind the transformation of the company. (Photo by Akira Kodaka)

RYOSUKE EGUCHI, Nikkei staff writer

TOKYO -- Propelled by the wave of keen interest in promising treatments for the coronavirus, Fujifilm Holdings is ready to shed its image as a camera film and copier maker and become known as an operation centered on health care.

The company announces its results for the year ended March on Friday. Market watchers are particularly interested in any comments regarding the flu drug Avigan, one of the most-talked-about candidates to treat COVID-19.

Sponsored Content

About Sponsored ContentThis content was commissioned by Nikkei's Global Business Bureau.